CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment

Last Updated: Thursday, September 19, 2024

Researchers conducted a retrospective study of patients who experienced liver toxicity following the use of CDK4/6 inhibitors. They reported on 22 cases of grade 3-4 hepatitis induced by ribociclib and abemaciclib. They concluded that although CD4/6 inhibitor-induced hepatitis is poorly described in the literature, the data support adding these drugs to the drug-induced autoimmune-like hepatitis category.

JHEP Reports

European Journal of Nuclear Medicine and Molecular Imaging

Predictive and prognostic value of 18F-FES PET/CT for patients with recurrent or metastatic breast cancer treated with endocrine therapy plus cyclin-dependent kinase 4/6 inhibitors

Chinese Journal of Cancer Research

Clinicopathological and molecular features of HR + /HER2 - breast cancer patients with distinct endocrine resistance patterns

Cancer Cell

CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety

Breast Cancer Research and Treatment

PTEN inactivating mutations are associated with hormone receptor loss during breast cancer recurrence

Journal of Cachexia, Sarcopenia, and Muscle

Low skeletal muscle radiodensity predicts response to CDK4/6 inhibitors plus aromatase inhibitors in advanced breast cancer

European Journal of Cancer

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer

Cancer Letters

TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer

Future Oncology

Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant

U.S. Food and Drug Administration

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

Journal of Clinical Oncology

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01

HR+ HER2- Breast Cancer Resource Center